LYMPHOMA TREATMENT AT A CROSSROADS
Complex Journey from Innovation to Patient impact
Two Acts, One Geopolitical Moment
Electronic Logs - The next phase of execution maturity in pharma
AI is in Every Pharma Strategy Deck
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Exploring New Molecular Targets for Anti-cancer Therapy
Clinical Professor, Department of Medicine, University of British Columbia
Amil Shah is Clinical Professor of Medicine at the University of British Columbia His practice focusses on gastrointestinal and lung cancers Among his administrativeacademic roles he chaired the Gastrointestinal Tumour Group at BC Cancer and served as Associate Dean of the VancouverFraser Medical Program at UBC His research interest is the molecular pathogenesis of cancer
Articles
There’s Finally Hope to Alleviate the Burden of Chronic Diseases
As societies in Asia grow older chronic diseases are becoming more and more prevalent They place serious strain not only on patients but also on caregivers and the healthcare system
Research Insights
Paradoxical Hypersusceptibility of Drug-resistant Mycobacterium tuberculosis to β-lactam Antibiotics
Abstract Mycobacterium tuberculosis M tuberculosis is considered innately resistant to lactam antibiotics However there is evidence that susceptibility to lactam antibiotics in combination with lactamase inhibitors is variable among clinical isolates and these may present therapeutic options for drugresistant cases Here we report o
Case Studies
Effect Of Process And Formulation Variables On The Preparation Of Parenteral Paclitaxel-loaded Biodegradable Polymeric Nanoparticles: A Co-surfactant Study
Abstract Recent years have seen significant effort devoted to formulate therapeutic agents in biocompatible nanocomposites such as nanoparticles nanocapsules micellar systems and conjugates as drug delivery systems Application of nanotechnology for diagnosis monitoring disease therapy and control of biological systems was referred to as nanomedicin
Techno Trends
Novel Elecsys Growth Differentiation Factor-15 (GDF-15) Assay Discovered for Cancer Treatment
Elecsys GDF assay discovered as a Companion Diagnostic CDx for the treatment of cancer It helps in finding patients suitable for innovative treatment addressing unintentional weight loss in cancer patients Elecsys GDF a quantitative serologic which uses the format of sandwich test
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
How Ready are Cellulose Nanocrystals in Delivery of Anticanceragents?
Researcher, Donghua University
Lipid Based Drug Delivery Systems
Venu Madhav Katla working as Professor in Department of Pharmaceutics and having over 15 years of teaching and research experience. He had more than 15 research and review publications. He is having 10 national as well as international presentations in his credit. He guided around 25 M.Pharm and one Ph.D student (Pursuing).
Sridhar Babu Gummadi working as Professor and having over 18 years of teaching and research experience. He is having more than 20 research and review publications. Had 10 national as well as international presentations in his credit. He had one patent and one book as publication. He guided around 35 M.Pharm and 4 Ph.D students (Pursuing).
Somnath De working as Professor and have over 15 years of teaching and research experience. He had more than 20 research and review publications. He is having 10 national as well as international presentations in his credit. He filed one patent. He guided around 24 MPharm and 4 Ph.D students (Pursuing).
Nanovaccines
Dr. Priya Gupta is currently working as an Assistant Professor at Amity Institute of Pharmacy, Amity University, Noida and earned her Ph.D. in Pharmaceutics from Jamia Hamdard in 2024. Her area of research includes formulation development, novel drug delivery systems, nanoformulations. She has authored more than 15 articles in peer-reviewed national and international journals.
Dr. Disha Marwaha earned a Ph.D. in Biological Sciences from the CSIR-Central Drug Research Institute (CSIR-CDRI) in 2024 and currently serves as an Assistant Professor at Chandigarh University Uttar Pradesh. Her research encompasses nanomedicine, pharmacokinetics, formulation development, and targeted drug delivery systems. She has authored more than 22 articles in peer-reviewed international journals.
The New Pharmacovigilance Era
With over 15 years of experience, Aarti brings deep expertise across pharmaceutical contract research services and technology‑enabled drug discovery and development. She leads the Contract Research Services program, covering peripheral and ancillary service segments such as tech vendors, eClinical solution providers, central labs, and related ecosystems. Her strengths span market intelligence, forecasting, competitive benchmarking, and strategic opportunity assessment as well as growth advisory services, that consistently support executive decision‑making for global clients. She is regarded as a trusted growth expert, and is adept in supporting stakeholders navigate industry disruption, accelerate innovation, and seize transformative opportunities across the rapidly evolving Contract Services Landscape.
Redefining Therapeutics
Professor Mads Hald Andersen, DMSc, DScTech, PhD, is Director of the National Center for Cancer Immune Therapy, CCIT-DK, at Copenhagen University Hospital Herlev, Denmark. He discovered tumor microenvironment antigens and anti-regulatory T cells and defined their role in immune regulation. He initiated the immune modulatory vaccine concept and has authored more than 250 publications and 25 patents.
press releasesRead more...
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...
Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus
Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
Alvotech a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited a global pharmaceutical company with a strategic focus on specialty hospital and rare disease medicines today announced the submissi...
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals Inc a global commercialstage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases today announced the commercial launch of IMCIVREE setmelanotide in Japan to treat patients living with acquired hypothalamic obesity HO...
Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement
Scinai Immunotherapeutics Ltd a biopharmaceutical company operating a growing contract development and manufacturing organization CDMO alongside an immunologyfocused therapeutic development platform today announced that its wholly owned subsidiary Scinai Biopharma Services Ltd has entered into a def...
EventsRead more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWSRead more...
Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ
Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals
Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours
Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...
Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases
Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...
Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors
Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...
Mint Pharmaceuticals and Bayer Expand Medicine Distribution in Canada
Mint Pharmaceuticals and Bayer have expanded their distribution partnership in Canada to include several additional medicines across womens health cardiovascular care and anticoagulation
